Red yeast rice stimulates bone formation in rats

Nutrition Research

Volumn 26, Issue 3, 2006, Pages 124-129

  Gutierrez, Gloria E ^a   Mundy, Benjamin ^a,c   Rossini, Gianni ^a   Garrett, I Ross ^a   Chen, Stephen T ^b   Mundy, Gregory R ^a,c  

^a OsteoScreen   (United States)

^b STC International Inc   (United States)

^c Marathon Nutrifoods   (United States)

Author keywords

Bone anabolic activity; HMG CoA inhibitors; Osteoporosis; Rats; Red yeast rice; Statins

Indexed keywords

MEVINOLIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIET; FEMALE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RAT; RED YEAST RICE; RICE;

ANAS PLATYRHYNCHOS; MONASCUS PURPUREUS;

EID: 33747693755     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nutres.2006.02.006     Document Type: Article

References (30)

1. Mundy G.R., Garrett I.R., Harris S.E., Chan J., Chen D., Rossini G., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286 (1999) 1946-1949
2. Sugiyama M., Kodama T., Konishi K., Abe K., Asami S., and Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 271 (2000) 688-692
3. Garrett I.R., Esparza J., Chen D., Zhao M., Gutierrez G., Escobedo A., et al. Statins mediate their effects on osteoblasts by inhibition of HMG-CoA reductase and ultimately BMP2. J Bone Miner Res 15 Suppl (2000) s225
4. Henwood J.M., and Heel R.C. Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 36 4 (1988) 429-454
5. Serajuddin A.T., Ranadive S.A., and Mahoney E.M.J. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharm Sci 80 9 (1991) 830-834
6. The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344 (1994) 1383-1389
7. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
8. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
9. Sindermann J.R., Fan L., Weigel K.A., Troyer D., Muller J.G., Schmidt A., et al. Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. Atherosclerosis 150 2 (2000) 331-341
10. van de Donk N.W., Kamphuis M.M., Lokhorst H.M., and Bloem A.C. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16 7 (2002) 1362-1371
11. Bauer D.C., Mundy G.R., Jamal S.A., Black D.M., Cauley J.A., Harris F., et al. Statin use, bone mass and fracture: an analysis of two prospective studies. J Bone Miner Res 14 (1999) 1188
12. Edwards C.J., Hart D.J., and Spector T.D. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 355 (2000) 2218-2219
13. Chan K.A., Andrade S.E., Boles M., Buist D.S., Chase G.A., Donahue J.G., et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355 (2000) 2185-2188
14. Wang P.S., Solomon D.H., Mogun H., and Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283 (2000) 3211-3216
15. Ma J., Li Y., Ye Q., Li J., Hua Y., Ju D., et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 48 (2000) 5220-5225
16. Heber D., Yip I., Ashley J.M., Elashoff D.A., and Go V.L.W. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69 (1999) 231-236
17. Germershausen J.I., Hunt V.M., Bostedor R.G., Bailey P.J., Karkas J.D., and Alberts A.W. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun 158 (1989) 667-675
18. Heller R.A., and Gould R.G. Solubilization and partial purification of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. Biochem Biophys Res Commun 50 (1973) 859
19. Garrett I.R. Assessing bone formation using mouse calvarial organ cultures. Methods Mol Med 80 (2003) 183
20. Garrett I.R., Chen D., Gutierrez G., et al. Selective inhibitors of the chymotrypsin-like activity of the osteoblast proteasome are potent stimulators of bone formation in vivo and in vitro. J Clin Invest 111 (2003) 1771-1782
21. Stubbs R.J., Schwartz M., and Bayne W.F. Determination of mevinolin and mevinolinic acid in plasma and bile by reversed-phase high-performance liquid chromatography. J Chromatogr 383 (1986) 438
22. Oxlund H., Dalstra M., and Andreassen T.T. Statin given perorally to adult rats increases cancellous bone mass and compressive strength. Calcif Tissue Int 69 (2001) 299-304
23. Skoglund B., Forslund C., and Aspenberg P. Simvastatin improves fracture healing in mice. J Bone Miner Res 17 (2002) 2004-2008
24. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., and Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283 (2000) 3205-3210
25. Gutierrez G., Garrett I.R., et al. Dermal application of lovastatin to rats causes greater increases in bone formation and plasma concentration than when administered by oral gavage. J Bone Miner Res 15 (2000) S427
26. Endo A., and Monacolin K. A new hypocholesterolemic agent produced by a Monascus species. J Antibiot 32 8 (1979) 852-854
27. Li C., Zhu Y., Wang Y., Zhu J., Chang J., and Kritchevsky D. Monascus Purpureus-fermented rice (red yeast rice): a natural food product that lowers blood cholesterol In animal models of hypercholesterolemia. Nutr Res 18 1 (1998) 71-81
28. Qin S, Zhang W, Qi P, Zhao M, Dong Z, Li Y, et al. Elderly patients with primary hyperlipidemia benefited from treatment with a Monascus purpureus rice preparation: a placebo-controlled, double-blind clinical trial. American Heart Association 1999. 39th Annual conference on Cardiovascular Disease Epidemiology and Prevention, Orlando, Fl.
29. Wang J., Lu Z., Chi J., Wang W., Su M., Kou W., et al. Multicenter clinical trial of serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional Chinese medicine. Curr Ther Res 58 12 (1997) 964-978
30. Man R.Y., Lynn E.G., Cheung E., et al. Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2). Mol Cell Biochem 233 (2002) 153-158